Spyre Therapeutics
Spyre Therapeutics Inc is an American clinical-stage biotechnology company focused on the discovery, development, and commercialization of next-generation antibody therapeutics for inflammatory bowel disease (IBD) and other immune-mediated gastrointestinal disorders. The company utilizes proprietary antibody engineering and protein design platforms to create therapeutic candidates targeting validated biological pathways with enhanced potency, half-life extension, and improved dosing profiles. Its core business activities encompass preclinical immunological research, clinical trial advancement, biopharmaceutical drug design, and regulatory compliance. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its drug research pipeline through public equity offerings and venture capital financing. Spyre Therapeutics holds a pioneering position in advanced immunology and IBD drug discovery. The company is headquartered in Waltham, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.
8 of the funds FundTelligence covers report a position in Spyre Therapeutics.
- Legal name
- Spyre Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 8
Funds holding Spyre Therapeutics
- Polar Capital Biotechnology Fund — Polar Capital · 3.1 % (largest positions only, October 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.94 % (full portfolio disclosed, September 2026)
- JPM Global Healthcare Fund — JPM · 0.93 % (full portfolio disclosed, June 2026)
- JPM US Small Cap Growth Fund — JPM · 0.9 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.59 % (full portfolio disclosed, October 2026)
- Schroder ISF Healthcare Innovation — Schroders · 0.57 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.08 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.04 % (full portfolio disclosed, September 2026)